Novartis AG (NVS) : During the past 4 weeks, traders have been relatively bearish on Novartis AG (NVS), hence the stock is down -4.37% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.41% relative to the S&P 500. The stock has risen by 0.09% in the past week indicating that the buyers are active at lower levels, but the stock is down -4.5% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 2.13% and the 50-Day Moving Average is 2.71%.The 200 Day SMA reached 1.57%. Novartis AG has dropped 2.37% during the last 3-month period . Year-to-Date the stock performance stands at -4.15%.
Novartis AG (NYSE:NVS): After opening at $79.05, the stock dipped to an intraday low of $78.91 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $79.455 and the buying power remained strong till the end. The stock closed at $79.38 for the day, a gain of 1.42% for the day session. The total traded volume was 1,352,967. The stocks close on the previous trading day was $78.27.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.